Choose CJC-1295 No DAC & Ipamorelin Vial Size | Real Peptides

Most researchers waste peptide doses because they choose the wrong vial size upfront. Mismatching study protocol duration with reconstitution shelf life means discarding unusable peptide after the 28-day bacteriostatic water window closes. A 5mg vial of CJC-1295 No DAC paired with a 5mg vial of Ipamorelin looks cost-efficient until you realise your protocol only requires 200mcg total per administration. Meaning you'll use 12% of each vial before the 28-day reconstitution clock runs out, wasting 88% of your investment. The math isn't obvious until you map dosing frequency against bacteriostatic water stability.

Our team has guided research labs through peptide procurement for years. The single biggest procurement error we see isn't peptide purity or supplier reliability. It's vial size selection relative to protocol design. This piece covers how to choose CJC-1295 No DAC & Ipamorelin vial size based on administration frequency, reconstitution volume, dosing precision requirements, and the non-negotiable 28-day shelf life of bacteriostatic water-reconstituted peptides.

How do you choose the right CJC-1295 No DAC and Ipamorelin vial size for your research protocol?

Match vial size to total peptide consumption within the 28-day post-reconstitution window. CJC-1295 No DAC and Ipamorelin are typically dosed at 100–300mcg per peptide per administration. A 2mg vial supports 6–20 administrations; a 5mg vial supports 16–50 administrations. Choose based on dosing frequency. Daily protocols require larger vials, while twice-weekly protocols are better served by 2mg vials to minimise waste after bacteriostatic water's 28-day shelf life expires.

The standard advice. 'buy the biggest vial for cost per milligram efficiency'. Only works if your protocol consumes the entire vial within four weeks of reconstitution. Beyond that window, peptide potency degrades regardless of refrigeration. CJC-1295 No DAC (also called Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, necessitating frequent dosing or combination with a GHRH analogue to sustain growth hormone release. Ipamorelin, a selective ghrelin receptor agonist, has a half-life of roughly two hours and is commonly stacked with CJC-1295 No DAC to amplify pulsatile GH secretion without elevating cortisol or prolactin. The synergy between these peptides drives their co-administration in research models studying anabolic signalling, tissue repair, and metabolic regulation.

This article covers vial size options for both peptides, reconstitution volume calculations, dosing precision across syringe types, cost-per-dose breakdowns, and what happens when vial size mismatches protocol duration.

Vial Size Options and Reconstitution Volume Trade-Offs

CJC-1295 No DAC and Ipamorelin are sold as lyophilised powders in 2mg, 5mg, and occasionally 10mg vials. Reconstitution volume. The amount of bacteriostatic water added. Directly determines dosing precision. A 2mg vial reconstituted with 2mL bacteriostatic water yields a 1mg/mL concentration, meaning every 0.1mL (10 units on a U100 insulin syringe) contains 100mcg of peptide. A 5mg vial reconstituted with 2mL yields 2.5mg/mL. Now every 0.1mL contains 250mcg, requiring smaller injection volumes but reducing margin for dosing error.

Larger reconstitution volumes increase precision but shorten shelf life indirectly. Once bacteriostatic water is added, the 28-day countdown begins regardless of whether you're drawing 0.05mL or 0.5mL per dose. Research protocols requiring doses below 100mcg benefit from higher dilution (more bacteriostatic water per vial) to avoid measuring volumes under 0.04mL, which most insulin syringes cannot reliably draw. We've found that 2mg vials reconstituted with 2mL bacteriostatic water offer the best balance between dosing precision and waste minimisation for twice-weekly protocols at 200–300mcg per peptide per administration.

Reconstitution isn't reversible. Once water contacts the lyophilised peptide, the stability clock starts. Refrigeration at 2–8°C slows degradation but doesn't stop it. Amino acid chains begin hydrolysing, disulfide bonds weaken, and biological activity declines measurably after 28 days even under ideal storage. Unreconstituted lyophilised peptides stored at −20°C remain stable for 12–24 months, but this window collapses the moment bacteriostatic water is introduced.

Dosing Frequency Determines Optimal Vial Size

A daily administration protocol consuming 200mcg CJC-1295 No DAC and 200mcg Ipamorelin per day requires 5.6mg of each peptide over 28 days. A 5mg vial falls short. You'll need two 5mg vials or one 10mg vial per peptide to avoid mid-protocol stockouts. A twice-weekly protocol at the same per-dose amount requires only 1.6mg total per peptide across four weeks, meaning a single 2mg vial per peptide covers the entire study duration with minimal waste.

Our team has reviewed this across hundreds of research setups. The dosing frequency mismatch. Buying 5mg vials for a sparse-administration protocol. Accounts for more wasted peptide than shipping damage, temperature excursions, and contamination combined. If your protocol administers peptides fewer than four times per week, 2mg vials are the correct choice. Daily or twice-daily protocols justify 5mg or 10mg vials, but only if total consumption within 28 days exceeds 80% of vial contents.

CJC-1295 No DAC's short half-life means it's typically dosed 1–3 times daily in research models aiming for sustained GH elevation. Ipamorelin's slightly longer half-life allows twice-daily dosing in most protocols. Stacking both peptides doesn't double the dose. They're synergistic, not additive. A common research dose is 100mcg CJC-1295 No DAC + 200mcg Ipamorelin administered simultaneously, 1–2 times daily. Over 28 days at twice-daily frequency, that's 5.6mg CJC-1295 No DAC and 11.2mg Ipamorelin. Justifying one 5mg + one 10mg vial or two 5mg vials of Ipamorelin alongside one 5mg vial of CJC-1295 No DAC.

CJC-1295 No DAC & Ipamorelin Vial Size Comparison

Key Takeaways

• CJC-1295 No DAC and Ipamorelin vial sizes range from 2mg to 10mg per peptide. Select based on total consumption within the 28-day post-reconstitution window, not cost per milligram.
• A 2mg vial reconstituted with 2mL bacteriostatic water yields 1mg/mL concentration, allowing precise 100mcg doses at 0.1mL per draw using standard U100 insulin syringes.
• Twice-weekly protocols at 200mcg per peptide require approximately 1.6mg total per peptide over 28 days. 2mg vials minimise waste to under 10%.
• Daily administration protocols consuming 200mcg per peptide per day require 5.6mg per peptide over 28 days. 5mg vials are insufficient; use 10mg vials or dual 5mg vials.
• Bacteriostatic water-reconstituted peptides remain stable for 28 days at 2–8°C. Beyond this window, biological activity declines regardless of visible appearance or refrigeration.
• CJC-1295 No DAC (Modified GRF 1-29) has a 30-minute plasma half-life; Ipamorelin has a two-hour half-life. Stacking both amplifies growth hormone pulses without cortisol elevation.

What If: CJC-1295 & Ipamorelin Vial Size Scenarios

What If I Buy 5mg Vials but Only Dose Twice Weekly?

You'll discard 60–70% of each vial after 28 days. A twice-weekly protocol at 200mcg per peptide consumes 1.6mg total per peptide over four weeks. Leaving 3.4mg per vial unused once bacteriostatic water's stability window closes. Refrigeration doesn't extend this. Peptide chains degrade through hydrolysis even at 2–8°C. The solution: buy 2mg vials, which cover eight doses with under 10% waste, or increase dosing frequency to three times weekly to justify the 5mg purchase.

What If I Reconstitute with More Bacteriostatic Water to Stretch the Vial?

Higher dilution improves dosing precision but doesn't extend shelf life or reduce waste. A 5mg vial reconstituted with 5mL instead of 2mL still expires 28 days post-reconstitution. You've only changed the concentration from 2.5mg/mL to 1mg/mL. This benefits protocols requiring sub-100mcg doses (easier to measure 0.08mL than 0.032mL), but it doesn't allow you to stretch the vial across more weeks. The 28-day bacteriostatic water limit is non-negotiable.

What If My Protocol Runs Longer Than 28 Days?

Plan multi-vial procurement upfront. A 12-week study dosed twice weekly requires three separate 2mg vials per peptide, each reconstituted at the start of a new 28-day cycle. Reconstitute only one vial at a time. Leave subsequent vials in lyophilised form at −20°C until needed. Attempting to extend a single reconstituted vial beyond 28 days introduces potency variability that confounds research outcomes. We've seen labs try to 'test' peptide activity beyond the window. It's not worth the protocol integrity risk.

What If I Need to Dose Multiple Subjects from One Vial?

Calculate total weekly peptide consumption across all subjects, then match vial size to that aggregate demand. Three subjects dosed at 200mcg per peptide twice weekly consume 4.8mg per peptide over 28 days. Justifying one 5mg vial per peptide with minimal waste. Single-subject protocols rarely justify vials larger than 2mg unless dosing daily. Multi-subject studies are where 10mg vials become cost-efficient, but only if total consumption exceeds 8mg within the 28-day window.

The Blunt Truth About CJC-1295 & Ipamorelin Vial Sizing

Here's the honest answer: buying the largest vial for 'better value per milligram' is false economy if your dosing schedule can't consume it within four weeks. A 10mg vial that's 40% cheaper per milligram than a 2mg vial costs you more when you discard 80% of it unused. The peptide research community repeats the 'bigger is better' advice without accounting for reconstitution shelf life. And suppliers don't correct this because larger vials mean higher per-transaction revenue.

The calculation that actually matters: total peptide required = (dose per administration in mcg) × (administrations per week) × 4 weeks ÷ 1000. If that number is under 1.8mg per peptide, buy 2mg vials. Between 1.8mg and 4.5mg, buy 5mg vials. Above 4.5mg, buy 10mg vials or split across multiple 5mg vials if your protocol allows staggered reconstitution. Anything else is paying for peptide you'll never use.

Storage and Handling Considerations for Multi-Week Protocols

Unreconstituted CJC-1295 No DAC and Ipamorelin vials stored at −20°C maintain potency for 12–24 months. Once reconstituted with bacteriostatic water, storage shifts to 2–8°C (standard refrigerator temperature) with a hard 28-day ceiling before biological activity begins measurable decline. Temperature excursions above 8°C. Even briefly. Accelerate peptide degradation through protein unfolding and oxidation. A vial left at room temperature (20–25°C) for six hours loses approximately 10–15% potency; 24 hours at room temperature renders it largely inactive.

Multi-vial procurement strategies reduce waste while maintaining protocol continuity. For studies extending beyond 28 days, purchase multiple 2mg or 5mg vials but reconstitute only one vial per peptide at a time. Store remaining vials at −20°C in their lyophilised state until the active vial nears depletion, then reconstitute the next vial. This approach prevents the 'start a 5mg vial, use 30%, discard 70%' scenario that defines inefficient peptide use.

Bacteriostatic water itself contains 0.9% benzyl alcohol as a preservative, inhibiting bacterial growth in multi-dose vials. But it doesn't prevent peptide hydrolysis or oxidation. The 28-day limit reflects peptide stability, not water sterility. Using peptides beyond this window doesn't introduce contamination risk; it introduces potency variability that compromises research reproducibility. If you're measuring anabolic markers, GH secretion, or tissue repair outcomes, using degraded peptide means your dosing is unknown. You might be administering 150mcg of active peptide when you think you're giving 200mcg.

For researchers working with Real Peptides, our small-batch synthesis process with exact amino-acid sequencing guarantees peptide purity at manufacture. But post-reconstitution handling determines whether that purity translates into consistent research outcomes. We've worked with labs optimising procurement strategies around vial size, and the pattern is consistent: matching vial size to protocol duration eliminates the single largest source of peptide waste without compromising dosing precision.

If vial size selection feels secondary to peptide purity or supplier reputation, consider this: a 99.5% pure peptide discarded at 70% remaining volume because the vial was oversized delivers worse cost-efficiency than a 98% pure peptide fully consumed from a correctly sized vial. Purity matters. But so does procurement planning. The decision to choose CJC-1295 No DAC & Ipamorelin vial size correctly is made before reconstitution, not after you've realised you can't use the remaining peptide before the 28-day window closes.

Experts in peptide research procurement plan vial sizing around dosing frequency first, cost per milligram second. Lyophilised stability is your asset. Reconstituted stability is your constraint. Work backwards from that constraint and you'll never waste peptide again.